Alaunos Therapeutics Announces Executive Financial Leadership Changes
Company Announcements

Alaunos Therapeutics Announces Executive Financial Leadership Changes

Alaunos Therapeutics (TCRT) has released an update.

Michael Wong resigned as Vice President, Finance of Alaunos Therapeutics, and Ferdinand Groenewald has been appointed in his stead through a consulting agreement effective immediately. Groenewald, a seasoned finance professional and CPA with extensive experience in various financial roles, will lead the company’s accounting and financial reporting for $15,000 per month plus expenses. His term is indefinite, with a 30-day termination notice by either party, and includes customary officer indemnification provisions. Groenewald’s prior roles include leadership positions at Muscle Maker, Inc., and board memberships at several Nasdaq-listed companies.

For further insights into TCRT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyZIOPHARM Oncology trading halted, news pending
Christine BrownAlaunos Therapeutics Inc (TCRT) Q4 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App